latest update:
[TrialBase DB]

trial summary · NCT07463807

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Multiple Myeloma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07463807phase PHASE1/PHASE2enrollment 162start 2027-04-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Carfilzomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving teclistamab and pomalidomide may be safe, tolerable and improve response by lowering myeloma cells to undetectable levels when compared to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with relapsed multiple myeloma.

Source record: https://clinicaltrials.gov/study/NCT07463807

Facts

registry idNCT07463807
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionRecurrent Multiple Myeloma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment162
start date2027-04-12
primary completion2029-03-31
completion2029-03-31
results postednot reported

Conditions

  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Carfilzomib
  • Computed Tomography
  • Dexamethasone
  • FDG-Positron Emission Tomography
  • Fludeoxyglucose F-18
  • Pomalidomide
  • Teclistamab

Countries

  • United States

Intervention types: DRUG, OTHER, PROCEDURE

Work with this record